Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma (VLA-011 CAPRA)

NCT02565992 is registered in ClinicalTrials.gov with Viralytics as lead sponsor.

NCT NCT02565992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02565992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma (VLA-011 CAPRA)
Lead sponsor
Viralytics
Phase
Phase 1
Overall status
Completed
Start date
December 17, 2015
Completion date
November 4, 2019
Enrollment
36 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma